Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glyceraldehyde-3-phosphate dehydrogenase pseudogene 67 (GAPDHP67) is one of many pseudogenes derived from the GAPDH gene. Pseudogenes are nonfunctional segments of DNA similar to functional genes but typically lack protein-coding capacity due to disabling mutations, truncations, or regulatory sequence loss. GAPDH has an unusually large number of pseudogenes in the human genome, most arising from retrotransposition, but these pseudogenes—including GAPDHP67—do not encode the active glycolytic enzyme and are not biological targets for drugs or therapeutic intervention[4].\n\nKey clarification:\nGAPDH itself is a functionally critical enzyme in glycolysis with many reported moonlighting roles in cell biology, disease, and drug response[1][2][3]. However, pseudogenes like GAPDHP67 are inactive genomic copies and not targets in drug discovery, diagnosis, or therapy[4]. No evidence supports their protein expression, functional activity, or role as a drug target.\n\nIf you need information on the active enzyme GAPDH, please specify—the current query targets a non-coding pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyceraldehyde-3-phosphate dehydrogenase pseudogene 67 (GAPDHP67).